Xi Liqiang, Lyons-Weiler James, Coello Michael C, Huang Xin, Gooding William E, Luketich James D, Godfrey Tony E
Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Clin Cancer Res. 2005 Jun 1;11(11):4128-35. doi: 10.1158/1078-0432.CCR-04-2525.
Lymph node status is a strong predictor of outcome for lung cancer patients. Recently, several reports have hinted that gene expression profiles of primary tumor may be able to predict node status. The goals of this study were to determine if microarray data could be used to accurately classify patients with regard to pathologic lymph node status, and to determine if this analysis could identify patients at risk for occult disease and worse survival.
Two previously published lung adenocarcinoma microarray data sets were reanalyzed. Patients were separated into two groups based on pathologic lymph node positive (pN+) or negative (pN0) status, and prediction analysis of microarray (PAM) was used for training and validation to classify nodal status. Overall survival analysis was performed based on PAM classifications.
In the training phase, a 318-gene set gave classification accuracy of 88.4% when compared with pathology. Survival was significantly worse in PAM-positive compared with PAM-negative patients overall (P < 0.0001) and also when confined to pN0 patients only (P = 0.0037). In the validation set, classification accuracy was again 94.1% in the pN+ patients but only 21.2% in the pN0 patients. However, among the pN0 patients, recurrence rates and overall survival were significantly worse in the PAM-positive compared with PAM-negative patients (P = 0.0258 and 0.0507).
Analysis of gene expression profiles from primary tumor may predict lymph node status but frequently misclassifies pN0 patients as node positive. Recurrence rates and overall survival are worse in these "misclassified" patients, implying that they may in fact have occult disease spread.
淋巴结状态是肺癌患者预后的有力预测指标。最近,有几份报告暗示原发性肿瘤的基因表达谱可能能够预测淋巴结状态。本研究的目的是确定微阵列数据是否可用于准确分类病理淋巴结状态的患者,并确定这种分析是否能识别有隐匿性疾病风险和较差生存率的患者。
对两个先前发表的肺腺癌微阵列数据集进行重新分析。根据病理淋巴结阳性(pN+)或阴性(pN0)状态将患者分为两组,并使用微阵列预测分析(PAM)进行训练和验证以分类淋巴结状态。基于PAM分类进行总生存分析。
在训练阶段,与病理结果相比,一个318基因集的分类准确率为88.4%。总体而言,PAM阳性患者的生存率明显低于PAM阴性患者(P<0.0001),仅局限于pN0患者时也是如此(P = 0.0037)。在验证集中,pN+患者的分类准确率再次为94.1%,但pN0患者仅为21.2%。然而,在pN0患者中,PAM阳性患者的复发率和总生存率明显低于PAM阴性患者(P = 0.0258和0.0507)。
对原发性肿瘤基因表达谱的分析可能预测淋巴结状态,但经常将pN0患者错误分类为淋巴结阳性。这些“错误分类”患者的复发率和总生存率较差,这意味着他们实际上可能有隐匿性疾病扩散。